According to Amy Zhang, Alger's executive vice president and small cap portfolio manager, Genedx may have more room to run with suspicious profits over the past year. She joined CNBC's “Power Ranch” on Wednesday, offering insights into the name of healthcare and two more radar stock stories on Wall Street. This is what Zhang said during his “Three Strains Lunch” that day. Genedx's stock in Genedx has skyrocketed by 1,000% over the past 12 months, and Zhang considers it to be an outstanding name for a space where genetic testing companies could grow even further. “They can do it faster and cheaper than their competitors while having very high accuracy,” the portfolio manager said. “They really solve a very important issue in healthcare and I think the company still has a very long runway for growth.” WGS 1Y Mountain WGS, 1 year Zhang believes its total addressable market (TAM) could reach over $40 billion. “It's very positive that we can continue to provide solid revenue profitability growth in the future,” Zhang added. Like Natera Genedx, the genetic test name Natera could face “surprising growth going forward,” Zhang said. The company's Crown Jewel is Signatera, a cancer monitoring test, she said. “Overall, we believe that in the long term, the addressable market will be around $60 billion,” the portfolio manager revealed during the segment. “The management's execution is amazing and it's no wonder.” Natera has fallen almost 7% in the past month, but has skyrocketed by over 66% over the past year. Zhang pointed out the launch of its Eyedose products at Glaukos. This is a sustained release implant intended to lower the water pressure of the eye, a condition that can lead to loss of vision. “I think it's a game changer and could be a huge hit,” she said. Glaukos' stock has flowed more than 32% in the past three months, but has earned almost 15% in the past year.
